Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BLINATUMOMAB Cause Therapy partial responder? 45 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 45 reports of Therapy partial responder have been filed in association with BLINATUMOMAB (BLINCYTO). This represents 0.5% of all adverse event reports for BLINATUMOMAB.

45
Reports of Therapy partial responder with BLINATUMOMAB
0.5%
of all BLINATUMOMAB reports
30
Deaths
4
Hospitalizations

How Dangerous Is Therapy partial responder From BLINATUMOMAB?

Of the 45 reports, 30 (66.7%) resulted in death, 4 (8.9%) required hospitalization, and 4 (8.9%) were considered life-threatening.

Is Therapy partial responder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BLINATUMOMAB. However, 45 reports have been filed with the FAERS database.

What Other Side Effects Does BLINATUMOMAB Cause?

Pyrexia (1,064) Acute lymphocytic leukaemia recurrent (977) Cytokine release syndrome (952) Off label use (590) Death (588) Neurotoxicity (530) Drug ineffective (345) Headache (335) Neutropenia (265) Febrile neutropenia (262)

What Other Drugs Cause Therapy partial responder?

CYCLOPHOSPHAMIDE (1,397) RITUXIMAB (1,219) DEXAMETHASONE (1,199) PREDNISONE (1,176) PEMBROLIZUMAB (1,125) CARBOPLATIN (1,096) DOXORUBICIN (834) METHOTREXATE (775) VINCRISTINE (707) ETOPOSIDE (670)

Which BLINATUMOMAB Alternatives Have Lower Therapy partial responder Risk?

BLINATUMOMAB vs BLONANSERIN BLINATUMOMAB vs --BLOOD-COAGULATION FACTOR VIII FUSION PROTEIN WITH IMMUNOGLOBULIN G1 , ,-BIS WITH IMMUNOGLOBULIN G1 BLINATUMOMAB vs BOCEPREVIR BLINATUMOMAB vs BOCOCIZUMAB BLINATUMOMAB vs BONIVA

Related Pages

BLINATUMOMAB Full Profile All Therapy partial responder Reports All Drugs Causing Therapy partial responder BLINATUMOMAB Demographics